Polymorphic forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter “Compound A-1,4-dioxane/water solvate”), wherein the crystalline form is characterized by an X-ray powder diffraction pattern comprising diffraction angles (°28), when measured using Cu Ku radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18.6, 20.3, 24.7, 25.0, and 26.5.
1. A crystalline form of a sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide, wherein the crystalline form is characterized by an X-ray powder diffraction pattern substantially in accordance with FIG. 3 .
2. A crystalline form of a sodium salt of claim 1 , wherein the crystalline form is characterized by an X-ray powder diffraction pattern containing diffraction angles, when measured using Cu K α radiation, at about 5.6, 17.7, 22.8, 24.3, 28.6, and 34.5° 28.
3. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum containing peaks at about 718, 1158, 1302, 1588, 1596, and 1636 cm −1 .
4. The crystalline form of claim 1 , wherein the crystalline form provides a Raman spectrum substantially in accordance with FIG. 8 .
5. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
6. A method of preparing a pharmaceutical composition comprising admixing the crystalline form of claim 1 and a pharmaceutically acceptable carrier.
7. The crystalline form of claim 1 , wherein the crystalline form differential scanning calorimetry thermogram profile is substantially in accordance with FIG. 12 .